Limei Ai
YOU?
Author Swipe
View article: Supplementary Figure S4 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Supplementary Figure S4 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA Open
Supplementary Figure S4. Temporal change of tumor content in pre-HCC samples. (A) Temporal change of tumor content using blood samples collected 0 to 7 years before clinical diagnosis of HCC. The horizontal dashed line in red indicates cut…
View article: Supplementary Figure S3 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Supplementary Figure S3 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA Open
Supplementary Figure S3. Distribution of the tumor fraction by baseline characteristics among 67 hospital HCC patients. (A) Distribution of the tumor fraction by age, sex, serum alpha-fetoprotein (AFP), Child–Pugh score, and tumor size. (B…
View article: Supplementary Figure S1 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Supplementary Figure S1 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA Open
Supplementary Figure S1. Genome-wide copy number profile change in eight HCC patients before and after surgery. The colors green, blue, dark red, and red correspond to copy number deletion, neutral, gain, and amplification, respectively.
View article: Supplementary Table S2 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Supplementary Table S2 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA Open
Supplementary Table S2. Cox regression analyses of factors related with overall survival (OS) among 67 hospital HCC patients. Univariate and multivariate Cox models were used to calculate hazard ratio (HR) and 95% confidence interval (CI).…
View article: Supplementary Figure S4 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Supplementary Figure S4 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA Open
Supplementary Figure S4. Temporal change of tumor content in pre-HCC samples. (A) Temporal change of tumor content using blood samples collected 0 to 7 years before clinical diagnosis of HCC. The horizontal dashed line in red indicates cut…
View article: Supplementary Table S1 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Supplementary Table S1 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA Open
Supplementary Table S1. Baseline characteristics of 67 hospital HCC patients, and patients treated by surgery or TACE with post-treatment sample.
View article: Supplementary Table S2 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Supplementary Table S2 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA Open
Supplementary Table S2. Cox regression analyses of factors related with overall survival (OS) among 67 hospital HCC patients. Univariate and multivariate Cox models were used to calculate hazard ratio (HR) and 95% confidence interval (CI).…
View article: Data from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Data from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA Open
Purpose:The objective of the study was to evaluate the use of tumor content in circulating cell-free DNA (ccfDNA) for monitoring hepatocellular carcinoma (HCC) throughout its natural history.Experimental Design:We included 67 patients with…
View article: Supplementary Figure S1 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Supplementary Figure S1 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA Open
Supplementary Figure S1. Genome-wide copy number profile change in eight HCC patients before and after surgery. The colors green, blue, dark red, and red correspond to copy number deletion, neutral, gain, and amplification, respectively.
View article: Supplementary Figure S2 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Supplementary Figure S2 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA Open
Supplementary Figure S2. Genome-wide copy number profile change in seven HCC patients before and after transarterial chemoembolization (TACE). The colors green, blue, dark red, and red correspond to copy number deletion, neutral, gain, and…
View article: Supplementary Figure S2 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Supplementary Figure S2 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA Open
Supplementary Figure S2. Genome-wide copy number profile change in seven HCC patients before and after transarterial chemoembolization (TACE). The colors green, blue, dark red, and red correspond to copy number deletion, neutral, gain, and…
View article: Supplementary Table S1 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Supplementary Table S1 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA Open
Supplementary Table S1. Baseline characteristics of 67 hospital HCC patients, and patients treated by surgery or TACE with post-treatment sample.
View article: Supplementary Figure S3 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Supplementary Figure S3 from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA Open
Supplementary Figure S3. Distribution of the tumor fraction by baseline characteristics among 67 hospital HCC patients. (A) Distribution of the tumor fraction by age, sex, serum alpha-fetoprotein (AFP), Child–Pugh score, and tumor size. (B…
View article: Data from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA
Data from Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA Open
Purpose:The objective of the study was to evaluate the use of tumor content in circulating cell-free DNA (ccfDNA) for monitoring hepatocellular carcinoma (HCC) throughout its natural history.Experimental Design:We included 67 patients with…